The pills detection system is built based on the Feature Pyramid NetworkConvolution Normal Network (CNN). Two-stage CNN architecture is used for pills localizationpill classification. The accuracyexecution time of the pill detection are 900.02s, respectively.

Diabetes is now still an incurable disease. Beta cell failure is one of common causes. No drugs for this failure have been developed. This invention is to developapply PS1 to treatreverse diabetes. PS1 is a first-in-class small-molecule drug, which targets beta cells by improving their survivalfunction. As a result, PS1 can treatreverse diabetes. The anti-diabetic mechanism of

Nanopharmaterial is a term by combining pharmaceuticalmaterial via nanotechnology. Here we demonstrate this concept by developing a novel nanopharmaterial, so called 177Lu-Gold nanostar (AuNS). 177Lu is a therapeutic radionuclide emitting moderate-energy beta particles as well as gamma rays for SPECT/CT-based imaging diagnosis. Nanostar can target tumors by enhanced permeability retention (EPR) effectsowns the photothermal therapeutic potent. The core technology is to integrate radionuclidenanomaterial to perform a new radio-nanopharmaterial for tumor target theranostic purpose.

The key technology of Patient Derived Tumor Spheroids (PDTS) is to create an in-vitro patient tumor microenvironmenttumor-like properties, furthermore, predict various cancer antidrug effectiveness to each patient via the high-throughputhigh-quality cell viability detectionbiomarker analysis. Therefore, this project established several technologies including extracellular matrix fabrication, bioink design, cell population identification,tumor physiological environment for the upon goal.

Through combining the cutting-edge technology of TD-ESI/MS to its comprehensive database library of toxicants, a fast-track toxicant analytical platforma set of standard operating procedures are developed that enables the emergency physicians to access correct toxicological information within a short turnaround timerescue the poisoned patients based on accurate laboratory data.

The present invention discloses the germplasm bank of medicinal coral producing new targeted anti-cancer agent and their aquaculture technology platform. The medicinal corals are collected in Kenting, located at the southern tip of Taiwan. In response to the unmet medical needs of new anti-cancer drugs, our research results will provide more diverse types of new drug targets and lead compounds in the "new drug development-new drug discovery and exploration period".

We provide antibody-based solutions to human diseases with short development course at low cost, are based on the phage-displayed GH (Generic Human) synthetic antibody libraries designedconstructed with enabling approaches, leading to the throughput capacities to uplift the innovativenessproductivity in developing antibody therapeuticsdiagnostics. In conjunction with the core technologies, antibody bioinformatics capable of extracting knowledge from big data of human antibody repertoires is used to elucidate human antibody responsesto assist antibody library design.

Our present invention firstly provides a new ultrasound (US)-multifunctional microbubble (MB) which can be applied to a topical region of the body surface of organisms by applyingsputtering, instead of using injection. Some interesting topics have been explored: 1. US-aided MBs facilitate the delivery of drugs to the inner ear via the transcanal method, 2. drug-carrying modified MB combine wit

"Establish an immunological-based platform for nano drug: 1. Establish macrophages as an in vitro cell-based testing platform 2. Safety assessmentimmunomodulatory effects of nano drugs 3. Gold nanodots as a specific target of Nrf2 pathway against chronic diseases."

(1) High flux mode for integrated measurements of SAXS/WAXS/UV-Vis-absorption/Refractive-index/Multi-angle-light-scattering (MALS) with an online high-performance liquid chromatography (HPLC) instrument, suitable for exploring biomacromolecular solution structures of a wide length scale and structural kinetics down to microsecond time scale. (2) Ultra SAXS (USAXS) mode for resolving hierarchical structures of bio-machinery assembly up to a few um length scale. (3) Anomalous SAXS mode for metal or mineral distributions (including calcium) in bio organelle or drug carriers. (4) Microbeam SAXS/WAXS mode for structural mapping of the textures or specific infected cells in natural/synthetic bio-tissues, organelles, or biomaterials.

1.High flux mode for integrated measurements of SAXS/WAXS/UV-Vis-absorption/Refractive-index/Multi-angle-light-scattering (MALS) with an online high-performance liquid chromatography (HPLC) instrument, suitable for exploring biomacromolecular solution structures of a wide length scalestructural kinetics down to microsecond time scale. 2.Ultra SAXS (USAXS) mode for resolving hierarchical structures of bio-machinery assembly up to a few m length scale. 3.Anomalous SAXS mode for metalmineral distributions (including calcium) in bio organelledrug carriers.

Due to the recent outbreak of COVID-19ongoing mutants, we developed a coronavirus variant protein microarray that includes all the current spike mutationsthe wild-type viral antigensapplied in detecting immune responsesdrug specificities. We filed the patientspublished our findings in the Analytical Chemistry. Besides massive production of the coronavirus protein microarray, we also collaborated with a scanner company, developed artificial intelligence software,collaborated with suppliers. We are welcome any sort of collaboration.

In order to improve the disease-selectivitysafety of antibody drugs, we use the autologous hinge as an antibody lockuse protease substrate peptide as linker to generate pro-antibody. Only in the disease area, the overexpressed protease will restore the function of the antibody. The antibody lock can improve the safety of antibodiesthe quality of patient medications. This technology has global patents (granted in 15 countries)technology transfer experience. We believed that the universal antibody lock will bring a revolutionary breakthrough in antibody drugs.

Our core generated several types of transgenic micea stable humanized ACE2 mice using a combi-CRISPR genetic engineering technique. We hope these mouse models can help to dissect COVID-19 pathogenic mechanismthe interaction(s) between spike proteinACE2 K353.

This invention is to apply PS1 to treatreverse T2D. The invention can be developed into small-molecule drugs. Those are first-in-class drugs for T2D because its novel anti-diabetic mode of action.

This technology is a development drug lead aiming to meet the medical needs of patients with small cell lung cancer. Through disturbing MYC-Aurora A interaction and inducing degradation of MYC oncoprotein, this bioavailable kinase inhibitor could serve as a potential treatment entity for SCLC.

This project will establish a National biobank consortium of Taiwan (NBCT) through the fund supportgovernance from the government. All Alliance will follow the same SOP for the biomaterial collectionhave the same quality of the biosample. Adequateconsistent clinical data will also be established under well information security management. Since the contents of the biobanks from different institute are quite different, we will be able to quickly establish a largecomprehensive biobank network. In line with the needs of biotechnology pharmaceutical, artificial intelligence, auxiliary medicalother industries.

"1. New method to prepare (3S, 3’S)astaxanthin, with high yield, high stabilityharmless to organism 2. The method has variety of biological activities anti-oxidation, anti-agingpromote damage tissue repair 3. It has anti-cancer potential, especially effective against metastatic cancer cells 4. Applied as Multifunctional medical supplies, functional foods, functional drinks, cosmeticsmaintenance products"

These stimuli-switchable nanoparticles coated with the cleavable outer polymer coatingmultifunctional peptides may afford a new platform for anticancer drugmiR. These nanoparticles possess characteristics of environmental response, active targeting,gene/chemo combinatorial therapeutics, thus providing spatiotemporal control of posttranｓｃｒｉｐｔional gene regulation, smart nuclear/mitochondrial localization,simultaneous inhibition of multiple progression pathways of tumor cells for enhancing antitumor efficacysafety of cancer therapy.

Current mainstream pharmacotherapy of glaucoma is the delivery of intraocular pressure-lowering medication via topical instillation. But, this dosage form has practical limitations due to well-known ocular barriers to drug transport. For the first time, highly efficient compound eye drop formulation is designed based on the idea of innovative glutathione-functionalized gelling materials. Our biomaterials-based ophthalmic drops can better improve drug bioavailabilityantiglaucoma efficacy than currently marketed eye drops, thereby showing future clinical translational potential.

This technology is mainly solved the side effects of anti-obesity drug, including soft stoolsoily stools,regulate oil absorptionmetabolism as an additive in food. During the experiment, the curing phenomenon of MSNs/oiloily stool reduction in animal were observed. In conclusion, MSNs can effectively reduce the side effects of Orlistatelevating life quality.

A high-sensitivity quantitative ELISA detection system for the large HBV surface (LHBS) protein was developed. It includes monoclonal antibodies for LHBSchemiluminescent sandwich ELISA method. Clinical tests of the ELISA prodcuts have been performed in CHB cases. The LHBS detection methodsproducts have been filed for US provisional patentwill be submitted for the IVD approval.

BPRSJ338 exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19 as a first-in-class drug. BPRSJ338 also potently inhibits against broad-spectrum coronaviruses including SARS-CoV-2, SARS-CoV, HCoV-229E, HCoV-OC43, TGEV, FIPV and MHV. Related US and Taiwan patents have been granted.​ Therefore it is also applicable to fight against severe evolving coronaviruses in the future.

Lung-on-minilab is designed as a tool for personalized healthcarewill contribute in precision medicine. Here, the tumor microenvironment was reconstituted using liquid dielectrophoresisarranged as lung tissue. The size of pattern can be customized as stages of cancer. Additionally, this chip was equipped a gradient microfluidic channel which enabled testing combination of medications. This is the first device where chemotherapyimmunotherapy medications can be tested together. This will improve the screening timeserve as an alternative for patients in therapeutic try.

ULF Raman spectroscopy utilizes novel VHG filters to spectrally clean up the laser line before ULF Raman spectroscopy is measured with a single grating spectrometer in conjunction with CCD camera. The availabilityaccessibility of UFL Raman spectroscopy opens new opportunity to reveal key information such as intermolecular structure characterization, pharmaceutical polymorph identification,material phaseinterfacial structure determination.

Our solution is able to noninvasively reconstruct 3D skin microstructuremicroangiography with micrometer-scale resolutions for diagnoses of skin disorders. Moreover, various skin parameters can be quantitatively evaluated from 3D images according to the proposed algorithms, including the thickness of stratum corneum, the thickness of epidermis, water concentration, collagen concentration,skin roughness. The developed technique can be applied to different clinical environments including hospitalscosmetic clinics for diagnosesanalyses of skin.

The novel drug-eluting contact lens is a great substitute for traditional eye drops, which are plagued by problems, such as low drug administration efficiency, discomfort,repeated dosing. Drugs can stay on the eyeball for a sufficient period of time. Patients can have access to treatment in an appropriate state at any time. With these advantages, the novel drug-eluting contact lens is expected to become a new method for the treatment of ophthalmic diseasesfor the recovery of patients after ophthalmic surgery. It has broad application prospects in the treatment of ophthalmic diseases.

We propose an AI dynamics drug repurposing platform applicate on COVID-19. This platform analyzed a large number of structures of SARS-CoV, MERS,cross-species coronavirus 3CL protease-ligand complexes to construct uncovering six flexible active site conformationspharmacophore clusters for SARS-CoV-2 3CL protease screening all FDA drugsfound four inhibitors within three months. Among them, JM206 had even demonstrated ten times better efficacy than Remdesivir in-vitro assayalso show the effect on the in-vivo hamster model to alleviate the symptoms caused by COVID-19.

An international collaboration led by Prof. Lih-Chu Chiou, College of Medicine, National Taiwan University, has identified a novel promising drug candidate, the α6-containing GABAA receptor-selective positive allosteric modulator, for the treatment of migraine, trigeminal painneuropsychiatric disorders (schizophreniaTourette syndrome).

R3CE (Rapid, Reproducible, Rare Cell 3D Expansion) is a clinically validated platform capable of generating single cell-derived organoids within one to four weeks. It outperforms currently 3D culture technologies in terms of yields, time to form organoids,easiness of operation. It also demonstrates similar yieldscost structure to 2D culture protocols. R3CE is ready for drug testing for all clinical samplesprovides sufficient quantity of genomic samples derived from cancer patients. It would help conduct clinical cancer treatment in the translational study.